Sign in

You're signed outSign in or to get full access.

Ann Cohen

Director at Niagen Bioscience
Board

About Ann Cohen

Ann Cohen, 64, has served as an independent director of Niagen Bioscience (NAGE) since April 2022; she chairs the Audit Committee, is designated an SEC “audit committee financial expert,” and serves on the Compensation Committee . She is Executive Vice President and Chief Financial Officer of The Institute of Internal Auditors (IIA) and is a Florida-licensed CPA and Certified Global Management Accountant with an M.S.F. from Florida International University and a B.S. in Accounting from the University of Florida . The Board has affirmatively determined her independence under Nasdaq rules .

Past Roles

OrganizationRoleTenureCommittees/Impact
The Institute of Internal Auditors (IIA)Executive Vice President & CFOOversees finance, project management, IT; deep governance/controls experience
Taylor Morrison Homes (formerly Taylor Woodrow)Senior financial leadership rolesLed GAAP/IFRS reporting, planning, ERM; large-scale homebuilder context
Starwood Vacation Ownership (division of Starwood Hotels & Resorts)Senior financial leadership rolesFinancial leadership at a NYSE company; acquired by Marriott in 2016
Sunterra CorporationSenior financial leadership rolesFinancial leadership at NYSE-listed vacation ownership company
PricewaterhouseCoopersAuditor (career start)Public accounting foundation; audit committee liaison experience

External Roles

OrganizationRoleTenureNotes
The Institute of Internal Auditors (IIA)Executive Vice President & CFOInternational professional association role, not a public company board
Other public company directorshipsNone disclosedNo other public boards disclosed in biography/proxy

Board Governance

  • Independence: The Board determined Cohen is independent under Nasdaq listing standards; Audit and Compensation Committees are fully independent .
  • Committee roles: Audit Committee Chair; Compensation Committee member; SEC “financial expert” designation .
  • Attendance: The Board met 4 times in 2024; each director attended at least 75% of Board and relevant committee meetings; five directors attended the June 20, 2024 annual meeting .
  • Committee meeting cadence FY2024: Audit (4), Compensation (7), Nominating & Corporate Governance (3) .
CommitteeRoleMeetings FY2024
AuditChair; Financial Expert4
CompensationMember7
Nominating & Corporate GovernanceNot a member3

Fixed Compensation

Component (FY2024)Amount
Annual cash retainer$40,000
Audit Committee Chair fee$20,000
Compensation Committee member fee (non-chair)$7,500
Total fees earned in cash$67,500

Notes:

  • Additional $30,000 annual retainer applies to Chairman or Lead Independent Director (not applicable to Cohen) .

Performance Compensation

AwardGrant DateUnitsExercise PriceVestingAccounting Fair Value
Annual non-employee director stock options6/20/202420,000$2.71100% on first anniversary$36,319 (ASC 718)
Initial election stock options (policy)40,000FMV on grantOver 3 years
  • Structure: Non-employee director compensation is a mix of cash and equity; annual option grants vest based on time, not performance .
  • Plan constraints: Non-employee director total compensation is capped at $600,000 per annual service period ($900,000 if first appointed during the period), measured at grant-date fair value for awards plus cash fees .

Performance Metrics Tied to Director Compensation

MetricDisclosure
Performance-based (TSR/Financial) conditionsNot applicable; director options are time-vested

Other Directorships & Interlocks

CompanyRoleCommittee Positions
None disclosed
  • No compensation committee interlocks; none of the Compensation Committee members (including Cohen) are officers/employees; no cross-board interlocks involving company executives in the past year .

Expertise & Qualifications

  • SEC audit committee financial expert; Florida CPA and CGMA credentials .
  • Deep GAAP/IFRS reporting, risk management, audit firm engagement, and SEC reporting experience from senior finance roles and PwC background .
  • CFO of IIA, reinforcing governance and internal audit expertise .

Equity Ownership

HolderShares Beneficially Owned% OutstandingOptions Exercisable within 60 DaysOptions Outstanding
Ann Cohen100,000 <1% 100,000 100,000
  • Ownership policy: Directors must hold at least 2x annual base retainer; compliance required within 5 years (with possible 3-year extension). All current directors are within compliance timelines; as of 12/31/2024, certain individuals had achieved required levels while others (including directors) were within deadlines .
  • Trading policies: Hedging, short sales, and derivative transactions in company securities are prohibited; Form 4 pre-clearance required for directors/executives .

Governance Assessment

  • Strengths

    • Independent audit chair with SEC “financial expert” credentials; oversight scope includes auditor selection, internal controls, related-party approvals, and annual cybersecurity risk review .
    • Strong committee cadence in FY2024 (Audit 4; Compensation 7), indicating active oversight; Board-level attendance above 75% threshold .
    • Compensation Committee uses external advisor (Exequity LLP since 2018) and conducted a compensation risk assessment concluding programs are not reasonably likely to have a material adverse effect .
    • Insider trading and ownership policies designed to align interests and prevent hedging .
  • Watch items / potential red flags

    • Director equity is time-based options with no performance conditions, which can weaken pay-for-performance alignment for board-level compensation .
    • Cohen’s beneficial ownership consists of options (100,000 exercisable within 60 days), suggesting limited ownership of outright common shares; monitor progress against 2x retainer ownership guideline by the five-year deadline from April 2022 .
    • Related-party transactions exist (e.g., Watson’s Agreement through prior significant shareholder and Nestlé/ NHSc supply agreement), though no specific conflicts tied to Cohen are disclosed; as Audit Chair, she is responsible for related-party review and approval oversight .
  • Independence and interlocks

    • Board affirmed Cohen’s independence; audit and compensation committees fully independent; no compensation committee interlocks or insider participation .

Overall, Cohen brings substantial financial governance expertise and independent oversight as Audit Chair. Key alignment consideration is the time-based nature of director equity and ensuring progress toward stock ownership guidelines, while continued vigilant handling of related-party approvals under Audit Committee procedures supports investor confidence .